| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pleural Neoplasms | 47 | 2024 | 485 | 6.700 |
Why?
|
| Mesothelioma | 47 | 2024 | 558 | 6.300 |
Why?
|
| Pneumonectomy | 58 | 2023 | 862 | 5.950 |
Why?
|
| Lung Neoplasms | 125 | 2024 | 12039 | 5.250 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 68 | 2024 | 5582 | 4.200 |
Why?
|
| Esophageal Neoplasms | 75 | 2024 | 3241 | 3.380 |
Why?
|
| Esophagectomy | 42 | 2024 | 946 | 2.950 |
Why?
|
| Pain, Postoperative | 12 | 2023 | 662 | 2.450 |
Why?
|
| Neoplasm Staging | 94 | 2024 | 14033 | 2.230 |
Why?
|
| Thoracic Surgical Procedures | 12 | 2022 | 260 | 1.850 |
Why?
|
| Postoperative Complications | 40 | 2024 | 5674 | 1.830 |
Why?
|
| Bupivacaine | 4 | 2020 | 74 | 1.740 |
Why?
|
| Thoracic Surgery, Video-Assisted | 14 | 2023 | 211 | 1.550 |
Why?
|
| Thoracic Surgery | 3 | 2021 | 284 | 1.550 |
Why?
|
| Adenocarcinoma | 51 | 2024 | 7920 | 1.520 |
Why?
|
| Neoplasm Recurrence, Local | 48 | 2022 | 10404 | 1.500 |
Why?
|
| Analgesics, Opioid | 7 | 2021 | 1467 | 1.410 |
Why?
|
| Robotic Surgical Procedures | 8 | 2023 | 536 | 1.390 |
Why?
|
| Retrospective Studies | 138 | 2024 | 39959 | 1.340 |
Why?
|
| Aged | 183 | 2024 | 73613 | 1.260 |
Why?
|
| Surgical Flaps | 14 | 2015 | 891 | 1.190 |
Why?
|
| Middle Aged | 197 | 2024 | 90533 | 1.150 |
Why?
|
| Pain Management | 5 | 2021 | 716 | 1.150 |
Why?
|
| Humans | 299 | 2024 | 270713 | 1.100 |
Why?
|
| Male | 218 | 2024 | 128479 | 1.100 |
Why?
|
| Propensity Score | 11 | 2021 | 772 | 1.090 |
Why?
|
| Thoracotomy | 8 | 2022 | 218 | 1.050 |
Why?
|
| Opioid-Related Disorders | 3 | 2019 | 420 | 1.050 |
Why?
|
| Radiosurgery | 8 | 2022 | 1389 | 1.030 |
Why?
|
| Female | 212 | 2024 | 148885 | 1.000 |
Why?
|
| Analgesia, Epidural | 2 | 2017 | 101 | 0.990 |
Why?
|
| Metastasectomy | 7 | 2023 | 209 | 0.980 |
Why?
|
| Radiotherapy, Intensity-Modulated | 8 | 2019 | 2178 | 0.970 |
Why?
|
| Chest Tubes | 4 | 2024 | 119 | 0.960 |
Why?
|
| Nerve Block | 3 | 2020 | 185 | 0.950 |
Why?
|
| Lung Diseases | 6 | 2021 | 751 | 0.890 |
Why?
|
| Treatment Outcome | 82 | 2024 | 33847 | 0.830 |
Why?
|
| Thymus Neoplasms | 5 | 2020 | 416 | 0.830 |
Why?
|
| Salvage Therapy | 13 | 2021 | 2124 | 0.800 |
Why?
|
| Heart Neoplasms | 8 | 2013 | 209 | 0.790 |
Why?
|
| Neoadjuvant Therapy | 33 | 2024 | 5246 | 0.770 |
Why?
|
| Intercostal Nerves | 3 | 2020 | 32 | 0.750 |
Why?
|
| Survival Rate | 50 | 2024 | 12530 | 0.740 |
Why?
|
| Length of Stay | 7 | 2024 | 1997 | 0.730 |
Why?
|
| Aged, 80 and over | 70 | 2024 | 31116 | 0.720 |
Why?
|
| Combined Modality Therapy | 43 | 2024 | 9053 | 0.720 |
Why?
|
| Esophagogastric Junction | 11 | 2023 | 558 | 0.720 |
Why?
|
| Dexmedetomidine | 1 | 2021 | 86 | 0.710 |
Why?
|
| Chemoradiotherapy | 15 | 2021 | 2037 | 0.670 |
Why?
|
| Carcinoma, Squamous Cell | 23 | 2023 | 5604 | 0.660 |
Why?
|
| Anesthetics, Local | 3 | 2020 | 179 | 0.660 |
Why?
|
| Hypesthesia | 1 | 2019 | 22 | 0.650 |
Why?
|
| Follow-Up Studies | 46 | 2024 | 15275 | 0.640 |
Why?
|
| Adult | 117 | 2024 | 82041 | 0.640 |
Why?
|
| Sarcoma | 10 | 2018 | 1851 | 0.640 |
Why?
|
| Chemotherapy, Adjuvant | 15 | 2021 | 4007 | 0.630 |
Why?
|
| Lung | 13 | 2023 | 3284 | 0.620 |
Why?
|
| SEER Program | 2 | 2019 | 1052 | 0.620 |
Why?
|
| Thoracic Neoplasms | 6 | 2019 | 363 | 0.600 |
Why?
|
| Thoracic Wall | 5 | 2020 | 188 | 0.600 |
Why?
|
| Ketamine | 1 | 2021 | 238 | 0.590 |
Why?
|
| Chemoradiotherapy, Adjuvant | 9 | 2021 | 561 | 0.580 |
Why?
|
| Disease-Free Survival | 31 | 2021 | 10268 | 0.580 |
Why?
|
| Time Factors | 37 | 2023 | 12978 | 0.570 |
Why?
|
| Endosonography | 7 | 2017 | 551 | 0.550 |
Why?
|
| Patient Discharge | 5 | 2022 | 699 | 0.540 |
Why?
|
| Radiation Injuries | 4 | 2016 | 1476 | 0.530 |
Why?
|
| Rectus Abdominis | 3 | 2004 | 92 | 0.530 |
Why?
|
| Lymph Nodes | 11 | 2021 | 3081 | 0.530 |
Why?
|
| Patient Selection | 8 | 2021 | 2029 | 0.530 |
Why?
|
| Survival Analysis | 34 | 2023 | 9281 | 0.510 |
Why?
|
| Colorectal Neoplasms | 9 | 2023 | 3707 | 0.510 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2015 | 34 | 0.500 |
Why?
|
| Prognosis | 50 | 2024 | 22528 | 0.490 |
Why?
|
| Chronic Pain | 1 | 2019 | 265 | 0.490 |
Why?
|
| Abdominal Muscles | 3 | 2003 | 71 | 0.490 |
Why?
|
| Margins of Excision | 3 | 2023 | 315 | 0.480 |
Why?
|
| Databases, Factual | 17 | 2024 | 2258 | 0.470 |
Why?
|
| Prospective Studies | 30 | 2024 | 13419 | 0.460 |
Why?
|
| Molecular Imaging | 4 | 2024 | 186 | 0.460 |
Why?
|
| Risk Factors | 29 | 2023 | 17861 | 0.420 |
Why?
|
| Replantation | 2 | 2010 | 60 | 0.420 |
Why?
|
| Hospital Mortality | 2 | 2018 | 1233 | 0.410 |
Why?
|
| Radiation Pneumonitis | 3 | 2016 | 313 | 0.410 |
Why?
|
| Esophagus | 5 | 2018 | 562 | 0.400 |
Why?
|
| Radiotherapy, Adjuvant | 15 | 2019 | 2272 | 0.400 |
Why?
|
| Proportional Hazards Models | 17 | 2024 | 5099 | 0.380 |
Why?
|
| Pleura | 4 | 2021 | 130 | 0.380 |
Why?
|
| Incidence | 14 | 2023 | 5825 | 0.380 |
Why?
|
| Thymoma | 4 | 2017 | 252 | 0.380 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2024 | 180 | 0.370 |
Why?
|
| Multivariate Analysis | 17 | 2023 | 4317 | 0.370 |
Why?
|
| Exercise | 1 | 2019 | 1221 | 0.370 |
Why?
|
| Cohort Studies | 22 | 2021 | 9463 | 0.370 |
Why?
|
| Ultrasonography, Interventional | 3 | 2013 | 425 | 0.370 |
Why?
|
| Recovery of Function | 4 | 2019 | 686 | 0.370 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2013 | 690 | 0.360 |
Why?
|
| Patient Readmission | 4 | 2021 | 571 | 0.350 |
Why?
|
| Tomography, X-Ray Computed | 16 | 2020 | 7787 | 0.340 |
Why?
|
| Vascular Neoplasms | 3 | 2009 | 112 | 0.330 |
Why?
|
| Anastomotic Leak | 2 | 2024 | 83 | 0.320 |
Why?
|
| Pulmonary Artery | 4 | 2009 | 520 | 0.310 |
Why?
|
| Acellular Dermis | 3 | 2020 | 101 | 0.310 |
Why?
|
| Treatment Failure | 8 | 2017 | 1430 | 0.300 |
Why?
|
| Kaplan-Meier Estimate | 19 | 2024 | 6257 | 0.300 |
Why?
|
| Preoperative Care | 10 | 2019 | 1581 | 0.300 |
Why?
|
| Sternum | 2 | 2013 | 97 | 0.300 |
Why?
|
| Lymphatic Metastasis | 15 | 2021 | 4969 | 0.290 |
Why?
|
| Cardiac Surgical Procedures | 5 | 2013 | 1149 | 0.290 |
Why?
|
| Wounds, Nonpenetrating | 2 | 2002 | 221 | 0.290 |
Why?
|
| Mastectomy, Modified Radical | 2 | 2000 | 75 | 0.290 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2021 | 1260 | 0.290 |
Why?
|
| Texas | 17 | 2020 | 6446 | 0.280 |
Why?
|
| Young Adult | 30 | 2024 | 22243 | 0.280 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2019 | 117 | 0.280 |
Why?
|
| Esophagoscopy | 4 | 2021 | 310 | 0.280 |
Why?
|
| Stomach Neoplasms | 6 | 2024 | 2339 | 0.270 |
Why?
|
| Treatment Refusal | 3 | 2019 | 127 | 0.270 |
Why?
|
| Perioperative Care | 3 | 2019 | 448 | 0.270 |
Why?
|
| Jejunum | 3 | 2015 | 229 | 0.270 |
Why?
|
| Neoplasm, Residual | 6 | 2018 | 1761 | 0.260 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2017 | 166 | 0.250 |
Why?
|
| Pain Measurement | 4 | 2020 | 1021 | 0.250 |
Why?
|
| Graft Survival | 5 | 2004 | 1076 | 0.250 |
Why?
|
| Campylobacter | 1 | 2005 | 29 | 0.250 |
Why?
|
| Campylobacter Infections | 1 | 2005 | 42 | 0.250 |
Why?
|
| Dasatinib | 2 | 2020 | 881 | 0.250 |
Why?
|
| Liver Abscess | 1 | 2005 | 37 | 0.250 |
Why?
|
| Neoplasms, Second Primary | 3 | 2018 | 1388 | 0.250 |
Why?
|
| Surgical Wound Infection | 3 | 2017 | 494 | 0.240 |
Why?
|
| Reoperation | 10 | 2019 | 1389 | 0.240 |
Why?
|
| Premedication | 1 | 2005 | 132 | 0.240 |
Why?
|
| Ipilimumab | 4 | 2023 | 765 | 0.240 |
Why?
|
| Chi-Square Distribution | 6 | 2017 | 1307 | 0.240 |
Why?
|
| Positron-Emission Tomography | 9 | 2021 | 2199 | 0.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 16 | 2023 | 16741 | 0.230 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2005 | 2140 | 0.230 |
Why?
|
| Melanoma | 4 | 2023 | 5599 | 0.230 |
Why?
|
| Mouth | 1 | 2005 | 125 | 0.230 |
Why?
|
| Chylothorax | 1 | 2024 | 42 | 0.230 |
Why?
|
| Barrett Esophagus | 2 | 2021 | 560 | 0.230 |
Why?
|
| Aftercare | 2 | 2022 | 250 | 0.230 |
Why?
|
| Liposomes | 2 | 2017 | 702 | 0.230 |
Why?
|
| Logistic Models | 8 | 2019 | 3429 | 0.230 |
Why?
|
| Intraoperative Care | 3 | 2020 | 272 | 0.220 |
Why?
|
| Abscess | 1 | 2005 | 192 | 0.220 |
Why?
|
| Drainage | 3 | 2021 | 461 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 12 | 2019 | 4054 | 0.220 |
Why?
|
| Octreotide | 1 | 2024 | 132 | 0.220 |
Why?
|
| Breast Neoplasms | 4 | 2023 | 16244 | 0.220 |
Why?
|
| Gastrointestinal Agents | 1 | 2024 | 119 | 0.220 |
Why?
|
| Risk Assessment | 13 | 2020 | 6766 | 0.220 |
Why?
|
| Platinum Compounds | 3 | 2020 | 129 | 0.220 |
Why?
|
| Bridged-Ring Compounds | 3 | 2020 | 194 | 0.220 |
Why?
|
| Area Under Curve | 2 | 2017 | 731 | 0.210 |
Why?
|
| Mediastinoscopy | 3 | 2013 | 33 | 0.210 |
Why?
|
| Thymectomy | 2 | 2020 | 80 | 0.210 |
Why?
|
| Lymphatic Diseases | 2 | 2012 | 128 | 0.200 |
Why?
|
| Seat Belts | 1 | 2002 | 24 | 0.200 |
Why?
|
| Pulmonary Embolism | 1 | 2006 | 342 | 0.200 |
Why?
|
| Thyroid Diseases | 1 | 2022 | 85 | 0.200 |
Why?
|
| Bronchogenic Cyst | 1 | 2002 | 21 | 0.200 |
Why?
|
| Enterotoxins | 2 | 1999 | 110 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 2 | 2011 | 2395 | 0.200 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2016 | 542 | 0.200 |
Why?
|
| Gastrectomy | 5 | 2024 | 476 | 0.200 |
Why?
|
| Matched-Pair Analysis | 1 | 2021 | 100 | 0.200 |
Why?
|
| Cartilage | 1 | 2002 | 111 | 0.200 |
Why?
|
| Adolescent | 21 | 2024 | 32689 | 0.200 |
Why?
|
| Prescriptions | 1 | 2021 | 60 | 0.190 |
Why?
|
| Radiopharmaceuticals | 5 | 2021 | 1342 | 0.190 |
Why?
|
| Mammaplasty | 3 | 2003 | 714 | 0.190 |
Why?
|
| Laparoscopy | 3 | 2022 | 1302 | 0.190 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2021 | 25 | 0.190 |
Why?
|
| Rats | 8 | 2005 | 6397 | 0.190 |
Why?
|
| United States | 10 | 2023 | 15828 | 0.190 |
Why?
|
| Biomarkers, Tumor | 8 | 2021 | 10726 | 0.180 |
Why?
|
| Taxoids | 4 | 2020 | 1019 | 0.180 |
Why?
|
| Acute Kidney Injury | 2 | 2020 | 758 | 0.180 |
Why?
|
| Fluid Therapy | 1 | 2022 | 192 | 0.180 |
Why?
|
| Goals | 1 | 2022 | 186 | 0.180 |
Why?
|
| Surgical Mesh | 3 | 2020 | 212 | 0.180 |
Why?
|
| 5'-Nucleotidase | 1 | 2021 | 63 | 0.180 |
Why?
|
| Vocal Cord Paralysis | 1 | 2002 | 95 | 0.180 |
Why?
|
| Healthcare Disparities | 2 | 2023 | 657 | 0.180 |
Why?
|
| Qualitative Research | 1 | 2024 | 638 | 0.180 |
Why?
|
| Sclerosing Solutions | 1 | 2000 | 27 | 0.180 |
Why?
|
| Duodenal Neoplasms | 1 | 2001 | 139 | 0.170 |
Why?
|
| Chyle | 2 | 2024 | 22 | 0.170 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2000 | 71 | 0.170 |
Why?
|
| Sclerotherapy | 1 | 2000 | 53 | 0.170 |
Why?
|
| Epigastric Arteries | 3 | 2005 | 45 | 0.170 |
Why?
|
| Peritoneal Neoplasms | 2 | 2023 | 866 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2024 | 879 | 0.170 |
Why?
|
| Tetracycline | 1 | 2000 | 106 | 0.170 |
Why?
|
| Polytetrafluoroethylene | 2 | 2017 | 109 | 0.170 |
Why?
|
| Leiomyoma | 1 | 2001 | 162 | 0.170 |
Why?
|
| Induction Chemotherapy | 2 | 2013 | 679 | 0.170 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 134 | 0.170 |
Why?
|
| Pain Perception | 1 | 2019 | 11 | 0.170 |
Why?
|
| Lung Transplantation | 1 | 2004 | 380 | 0.160 |
Why?
|
| Orthostatic Intolerance | 1 | 2019 | 7 | 0.160 |
Why?
|
| International Agencies | 3 | 2019 | 107 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 1032 | 0.160 |
Why?
|
| Cancer Care Facilities | 3 | 2018 | 907 | 0.160 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2022 | 709 | 0.160 |
Why?
|
| Microwaves | 1 | 2018 | 33 | 0.160 |
Why?
|
| Simulation Training | 1 | 2021 | 162 | 0.160 |
Why?
|
| Pain Threshold | 1 | 2019 | 134 | 0.160 |
Why?
|
| Aprotinin | 2 | 2009 | 30 | 0.160 |
Why?
|
| Radiotherapy | 3 | 2019 | 1858 | 0.160 |
Why?
|
| Sex Factors | 7 | 2020 | 2180 | 0.160 |
Why?
|
| Carcinoma, Papillary | 1 | 2022 | 566 | 0.150 |
Why?
|
| Thoracoscopy | 1 | 2019 | 103 | 0.150 |
Why?
|
| Antibodies, Bispecific | 2 | 1999 | 282 | 0.150 |
Why?
|
| Postoperative Care | 4 | 2021 | 726 | 0.150 |
Why?
|
| Immunogenetics | 1 | 2018 | 18 | 0.150 |
Why?
|
| Disease Progression | 7 | 2020 | 6881 | 0.150 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 924 | 0.150 |
Why?
|
| Operative Time | 1 | 2019 | 253 | 0.150 |
Why?
|
| Nomograms | 3 | 2020 | 312 | 0.150 |
Why?
|
| Carcinoid Tumor | 1 | 2020 | 282 | 0.150 |
Why?
|
| Natural Language Processing | 1 | 2018 | 112 | 0.150 |
Why?
|
| Hemostatics | 2 | 2009 | 82 | 0.150 |
Why?
|
| Ticlopidine | 1 | 2017 | 49 | 0.150 |
Why?
|
| Heparin | 1 | 2019 | 343 | 0.150 |
Why?
|
| Robotics | 1 | 2021 | 365 | 0.140 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2017 | 115 | 0.140 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2019 | 102 | 0.140 |
Why?
|
| Adenoma | 1 | 2022 | 738 | 0.140 |
Why?
|
| Stomach | 2 | 2012 | 396 | 0.140 |
Why?
|
| Cholelithiasis | 1 | 1997 | 49 | 0.140 |
Why?
|
| Gallbladder | 1 | 1997 | 68 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2021 | 669 | 0.140 |
Why?
|
| Hyperalgesia | 1 | 2019 | 245 | 0.140 |
Why?
|
| Vaccines, Subunit | 1 | 2017 | 125 | 0.140 |
Why?
|
| Anesthesia, General | 2 | 2016 | 224 | 0.140 |
Why?
|
| Bile | 1 | 1997 | 85 | 0.140 |
Why?
|
| Registries | 5 | 2018 | 2210 | 0.140 |
Why?
|
| Thoracoplasty | 1 | 2016 | 17 | 0.140 |
Why?
|
| Monitoring, Physiologic | 2 | 1993 | 515 | 0.140 |
Why?
|
| Radiotherapy, Conformal | 3 | 2007 | 898 | 0.140 |
Why?
|
| Medicare | 2 | 2019 | 926 | 0.130 |
Why?
|
| Gene Dosage | 3 | 2014 | 822 | 0.130 |
Why?
|
| Mutation | 6 | 2020 | 15917 | 0.130 |
Why?
|
| Surgical Oncology | 1 | 2019 | 212 | 0.130 |
Why?
|
| Analysis of Variance | 5 | 2018 | 2315 | 0.130 |
Why?
|
| Self Report | 2 | 2023 | 794 | 0.130 |
Why?
|
| Pain | 2 | 2022 | 1701 | 0.130 |
Why?
|
| Silicones | 1 | 1995 | 60 | 0.130 |
Why?
|
| Diaphragm | 1 | 2017 | 187 | 0.130 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2016 | 508 | 0.130 |
Why?
|
| Empyema | 1 | 1995 | 37 | 0.130 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 5332 | 0.130 |
Why?
|
| Age Factors | 8 | 2020 | 5441 | 0.130 |
Why?
|
| Predictive Value of Tests | 9 | 2020 | 4966 | 0.130 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 359 | 0.130 |
Why?
|
| Serous Membrane | 1 | 2015 | 9 | 0.130 |
Why?
|
| Lymphocytes | 3 | 2016 | 1273 | 0.130 |
Why?
|
| Pectoralis Muscles | 1 | 2015 | 25 | 0.120 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 1050 | 0.120 |
Why?
|
| Neoplasms | 4 | 2023 | 15949 | 0.120 |
Why?
|
| Thoracic Injuries | 1 | 1995 | 98 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2019 | 724 | 0.120 |
Why?
|
| Smoking Cessation | 1 | 2021 | 770 | 0.120 |
Why?
|
| Heart Atria | 3 | 2013 | 346 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 328 | 0.120 |
Why?
|
| Endoscopy | 1 | 2018 | 495 | 0.120 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2016 | 208 | 0.120 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 521 | 0.120 |
Why?
|
| Intraoperative Complications | 1 | 1997 | 287 | 0.120 |
Why?
|
| Cisplatin | 7 | 2020 | 2508 | 0.120 |
Why?
|
| Injections | 1 | 2015 | 284 | 0.120 |
Why?
|
| Dermatologic Surgical Procedures | 2 | 1993 | 109 | 0.120 |
Why?
|
| Laser-Doppler Flowmetry | 3 | 2004 | 64 | 0.120 |
Why?
|
| Circulating Tumor DNA | 1 | 2017 | 277 | 0.120 |
Why?
|
| Mucous Membrane | 1 | 2015 | 258 | 0.110 |
Why?
|
| Anticoagulants | 1 | 2019 | 777 | 0.110 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 206 | 0.110 |
Why?
|
| Sensitivity and Specificity | 6 | 2017 | 5157 | 0.110 |
Why?
|
| Gene Amplification | 2 | 2014 | 764 | 0.110 |
Why?
|
| Mediastinum | 4 | 2019 | 276 | 0.110 |
Why?
|
| Adjuvants, Immunologic | 1 | 2017 | 669 | 0.110 |
Why?
|
| Fistula | 1 | 1994 | 77 | 0.110 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2014 | 153 | 0.110 |
Why?
|
| Radiography | 5 | 2013 | 1994 | 0.110 |
Why?
|
| Rare Diseases | 1 | 2016 | 360 | 0.110 |
Why?
|
| Mastectomy | 1 | 2019 | 1554 | 0.110 |
Why?
|
| Trachea | 1 | 2015 | 301 | 0.110 |
Why?
|
| Surveys and Questionnaires | 4 | 2023 | 5923 | 0.100 |
Why?
|
| Biopsy | 4 | 2020 | 3490 | 0.100 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2024 | 604 | 0.100 |
Why?
|
| Esophagoplasty | 1 | 2012 | 28 | 0.100 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2013 | 124 | 0.100 |
Why?
|
| Genes, myc | 1 | 2014 | 372 | 0.100 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 1065 | 0.100 |
Why?
|
| Tissue Expansion | 1 | 1993 | 71 | 0.100 |
Why?
|
| Positron Emission Tomography Computed Tomography | 4 | 2021 | 881 | 0.100 |
Why?
|
| Comorbidity | 4 | 2019 | 2393 | 0.100 |
Why?
|
| Animals | 15 | 2023 | 61357 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 965 | 0.100 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2012 | 30 | 0.100 |
Why?
|
| Tumor Burden | 4 | 2020 | 2033 | 0.100 |
Why?
|
| Ribs | 2 | 2016 | 85 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 1958 | 0.100 |
Why?
|
| Necrosis | 2 | 2004 | 591 | 0.100 |
Why?
|
| Bronchi | 3 | 2017 | 325 | 0.100 |
Why?
|
| Cell Nucleus | 1 | 2017 | 1715 | 0.100 |
Why?
|
| Patient Safety | 1 | 2017 | 612 | 0.100 |
Why?
|
| Omentum | 1 | 2012 | 109 | 0.100 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 1908 | 0.100 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2000 | 1235 | 0.100 |
Why?
|
| Bone Neoplasms | 4 | 2016 | 2674 | 0.100 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2023 | 1404 | 0.090 |
Why?
|
| Camptothecin | 2 | 2004 | 540 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1854 | 0.090 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 1095 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 7317 | 0.090 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2012 | 165 | 0.090 |
Why?
|
| Electrocardiography | 1 | 2017 | 1146 | 0.090 |
Why?
|
| Preoperative Period | 3 | 2013 | 348 | 0.090 |
Why?
|
| Breast Implants | 1 | 1995 | 375 | 0.090 |
Why?
|
| Cause of Death | 3 | 2015 | 781 | 0.090 |
Why?
|
| Public Opinion | 1 | 2011 | 74 | 0.090 |
Why?
|
| Biopsy, Needle | 2 | 2013 | 1381 | 0.090 |
Why?
|
| Suction | 2 | 2002 | 123 | 0.090 |
Why?
|
| Drug Administration Schedule | 5 | 2019 | 3534 | 0.090 |
Why?
|
| Immunotherapy | 2 | 2024 | 3561 | 0.090 |
Why?
|
| Pericarditis | 1 | 2011 | 58 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2020 | 3945 | 0.090 |
Why?
|
| Neutrophils | 1 | 2015 | 855 | 0.090 |
Why?
|
| Heart Transplantation | 2 | 2008 | 904 | 0.090 |
Why?
|
| Radiation Tolerance | 3 | 2020 | 639 | 0.090 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2011 | 94 | 0.090 |
Why?
|
| Cost of Illness | 2 | 2023 | 506 | 0.090 |
Why?
|
| Protein Biosynthesis | 1 | 2013 | 986 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2018 | 1901 | 0.080 |
Why?
|
| Italy | 1 | 2010 | 190 | 0.080 |
Why?
|
| New Zealand | 2 | 2019 | 67 | 0.080 |
Why?
|
| Sepsis | 1 | 2015 | 673 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2013 | 626 | 0.080 |
Why?
|
| Transplantation, Autologous | 4 | 2012 | 2073 | 0.080 |
Why?
|
| Quality of Health Care | 1 | 2013 | 614 | 0.080 |
Why?
|
| ROC Curve | 1 | 2012 | 1250 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2023 | 2856 | 0.080 |
Why?
|
| RNA, Long Noncoding | 1 | 2014 | 617 | 0.080 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2011 | 216 | 0.080 |
Why?
|
| Remission Induction | 5 | 2013 | 3658 | 0.080 |
Why?
|
| Telephone | 2 | 2021 | 163 | 0.080 |
Why?
|
| Laser Therapy | 1 | 1993 | 467 | 0.080 |
Why?
|
| Odds Ratio | 3 | 2021 | 2299 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 2363 | 0.080 |
Why?
|
| Aorta | 1 | 2012 | 666 | 0.080 |
Why?
|
| Overweight | 1 | 2011 | 484 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2008 | 142 | 0.080 |
Why?
|
| Anastomosis, Surgical | 4 | 2012 | 370 | 0.080 |
Why?
|
| Radiation Dosage | 2 | 2019 | 1042 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2015 | 818 | 0.070 |
Why?
|
| Carcinogenesis | 1 | 2014 | 1034 | 0.070 |
Why?
|
| Fluorouracil | 5 | 2013 | 1990 | 0.070 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2007 | 34 | 0.070 |
Why?
|
| Oncogenes | 1 | 2011 | 697 | 0.070 |
Why?
|
| Adenofibroma | 1 | 2007 | 20 | 0.070 |
Why?
|
| Blood Loss, Surgical | 1 | 2009 | 295 | 0.070 |
Why?
|
| Prostatic Neoplasms | 2 | 2022 | 5869 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 2343 | 0.070 |
Why?
|
| Smoking | 4 | 2021 | 2549 | 0.070 |
Why?
|
| Radiotherapy Dosage | 4 | 2011 | 4020 | 0.070 |
Why?
|
| Hemostasis | 1 | 2007 | 98 | 0.070 |
Why?
|
| Statistics, Nonparametric | 3 | 2018 | 982 | 0.070 |
Why?
|
| Pemetrexed | 2 | 2017 | 100 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2008 | 324 | 0.070 |
Why?
|
| Aptitude Tests | 1 | 2006 | 7 | 0.070 |
Why?
|
| Pneumonia, Aspiration | 1 | 2006 | 45 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2011 | 2312 | 0.070 |
Why?
|
| Contrast Media | 2 | 2023 | 1505 | 0.070 |
Why?
|
| Consensus | 1 | 2011 | 1113 | 0.070 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2006 | 40 | 0.070 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2013 | 742 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2011 | 2227 | 0.070 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2006 | 41 | 0.070 |
Why?
|
| Child | 9 | 2023 | 30560 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 2017 | 2574 | 0.070 |
Why?
|
| Costs and Cost Analysis | 3 | 2015 | 310 | 0.070 |
Why?
|
| Skin Physiological Phenomena | 1 | 1986 | 40 | 0.070 |
Why?
|
| Genomics | 3 | 2024 | 2832 | 0.070 |
Why?
|
| Nausea | 2 | 2007 | 537 | 0.060 |
Why?
|
| Clinical Competence | 2 | 2021 | 1331 | 0.060 |
Why?
|
| Competency-Based Education | 1 | 2006 | 80 | 0.060 |
Why?
|
| Perioperative Period | 2 | 2016 | 149 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 682 | 0.060 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 238 | 0.060 |
Why?
|
| Pancreatectomy | 2 | 2024 | 690 | 0.060 |
Why?
|
| Heterografts | 2 | 2019 | 738 | 0.060 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2005 | 128 | 0.060 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2005 | 84 | 0.060 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2006 | 289 | 0.060 |
Why?
|
| Artifacts | 1 | 2007 | 537 | 0.060 |
Why?
|
| Epidemiologic Methods | 2 | 2017 | 249 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2005 | 311 | 0.060 |
Why?
|
| Dyspnea | 1 | 2007 | 420 | 0.060 |
Why?
|
| Awards and Prizes | 1 | 2005 | 88 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 2008 | 1057 | 0.060 |
Why?
|
| Spinal Neoplasms | 1 | 2009 | 671 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 1999 | 1719 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 4838 | 0.050 |
Why?
|
| Isotretinoin | 1 | 2003 | 161 | 0.050 |
Why?
|
| Leukocyte Count | 2 | 2015 | 727 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2019 | 1825 | 0.050 |
Why?
|
| Palliative Care | 2 | 2013 | 2176 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2023 | 232 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2021 | 1301 | 0.050 |
Why?
|
| Antineoplastic Agents | 5 | 2017 | 14638 | 0.050 |
Why?
|
| Hernia | 1 | 2002 | 45 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2024 | 518 | 0.050 |
Why?
|
| Income | 1 | 2023 | 232 | 0.050 |
Why?
|
| Veins | 1 | 2003 | 161 | 0.050 |
Why?
|
| Travel | 1 | 2023 | 191 | 0.050 |
Why?
|
| Renal Insufficiency | 1 | 2005 | 304 | 0.050 |
Why?
|
| Radiography, Thoracic | 2 | 2017 | 477 | 0.050 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 1828 | 0.050 |
Why?
|
| Mice, Inbred C3H | 2 | 1999 | 404 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 1656 | 0.050 |
Why?
|
| Skin | 3 | 2014 | 1281 | 0.050 |
Why?
|
| Models, Animal | 1 | 2004 | 657 | 0.050 |
Why?
|
| Hyperthermia, Induced | 1 | 2006 | 514 | 0.050 |
Why?
|
| Lymphoma | 1 | 2010 | 1516 | 0.050 |
Why?
|
| Pneumonia | 2 | 2007 | 793 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2023 | 464 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 2 | 2024 | 5258 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2014 | 2882 | 0.050 |
Why?
|
| Hypertension, Pulmonary | 1 | 2006 | 463 | 0.050 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2012 | 1831 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 1175 | 0.040 |
Why?
|
| Herniorrhaphy | 1 | 2002 | 181 | 0.040 |
Why?
|
| Neck | 1 | 2022 | 394 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 2051 | 0.040 |
Why?
|
| Exudates and Transudates | 1 | 2000 | 57 | 0.040 |
Why?
|
| Ultrasonography | 2 | 2019 | 1931 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2021 | 233 | 0.040 |
Why?
|
| Cytokines | 2 | 2020 | 2803 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2002 | 384 | 0.040 |
Why?
|
| Thyroidectomy | 1 | 2022 | 489 | 0.040 |
Why?
|
| Graft vs Host Disease | 1 | 2011 | 2811 | 0.040 |
Why?
|
| Sodium Chloride | 1 | 2000 | 159 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 482 | 0.040 |
Why?
|
| Cell Proliferation | 3 | 2018 | 7232 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2020 | 162 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2008 | 1464 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2000 | 263 | 0.040 |
Why?
|
| Foundations | 1 | 2019 | 21 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 3435 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2020 | 5417 | 0.040 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1999 | 107 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 1174 | 0.040 |
Why?
|
| Metaplasia | 1 | 2021 | 387 | 0.040 |
Why?
|
| Pressure | 2 | 2012 | 186 | 0.040 |
Why?
|
| Precision Medicine | 2 | 2020 | 1216 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 309 | 0.040 |
Why?
|
| CD4 Antigens | 1 | 1999 | 170 | 0.040 |
Why?
|
| CD8 Antigens | 1 | 1999 | 174 | 0.040 |
Why?
|
| Mice | 5 | 2023 | 35421 | 0.040 |
Why?
|
| Lymph Node Excision | 2 | 2018 | 2068 | 0.040 |
Why?
|
| Antigens, CD20 | 1 | 2019 | 207 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 1999 | 179 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2021 | 2360 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 338 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2021 | 481 | 0.040 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2002 | 349 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2023 | 783 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2021 | 7648 | 0.040 |
Why?
|
| Carcinoma | 2 | 2011 | 2610 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2021 | 1117 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2019 | 219 | 0.040 |
Why?
|
| Clonal Evolution | 1 | 2020 | 250 | 0.040 |
Why?
|
| Quebec | 1 | 2018 | 20 | 0.040 |
Why?
|
| Antibodies, Neoplasm | 1 | 1999 | 273 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 546 | 0.040 |
Why?
|
| Cetuximab | 1 | 2020 | 474 | 0.040 |
Why?
|
| Contraindications | 1 | 1998 | 153 | 0.040 |
Why?
|
| Carboplatin | 2 | 2016 | 889 | 0.040 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1997 | 93 | 0.040 |
Why?
|
| Immunization | 1 | 1999 | 383 | 0.040 |
Why?
|
| Catheterization | 1 | 2000 | 416 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2018 | 117 | 0.040 |
Why?
|
| Organoplatinum Compounds | 2 | 2013 | 707 | 0.040 |
Why?
|
| ErbB Receptors | 2 | 2020 | 2376 | 0.040 |
Why?
|
| Recurrence | 2 | 2005 | 4878 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 1999 | 376 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2018 | 14878 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 3054 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 896 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2005 | 856 | 0.030 |
Why?
|
| CD3 Complex | 1 | 1997 | 320 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2011 | 5415 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2004 | 727 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2018 | 747 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 4968 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2021 | 1723 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 1999 | 1553 | 0.030 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2002 | 526 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 866 | 0.030 |
Why?
|
| Cardiovascular Diseases | 2 | 2009 | 2219 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2017 | 6344 | 0.030 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2015 | 13 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2021 | 1568 | 0.030 |
Why?
|
| Glucose | 1 | 2021 | 1214 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 2658 | 0.030 |
Why?
|
| Sarcoma, Synovial | 1 | 2016 | 141 | 0.030 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2000 | 690 | 0.030 |
Why?
|
| Anemia | 1 | 2001 | 725 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2006 | 1442 | 0.030 |
Why?
|
| Oxygenases | 1 | 2014 | 26 | 0.030 |
Why?
|
| Scoliosis | 1 | 2016 | 148 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2005 | 2459 | 0.030 |
Why?
|
| Gene Editing | 1 | 2017 | 229 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2017 | 440 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 1246 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2021 | 1874 | 0.030 |
Why?
|
| Chondrosarcoma | 1 | 2016 | 213 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 1995 | 198 | 0.030 |
Why?
|
| Indoles | 1 | 2020 | 1029 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 1295 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 666 | 0.030 |
Why?
|
| Chylomicrons | 1 | 1994 | 9 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2016 | 283 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 7916 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 1135 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1999 | 1019 | 0.030 |
Why?
|
| Creatinine | 1 | 2016 | 525 | 0.030 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2016 | 159 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 2356 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 362 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 1691 | 0.030 |
Why?
|
| Kidney | 1 | 2022 | 2102 | 0.030 |
Why?
|
| Blood Gas Monitoring, Transcutaneous | 1 | 1993 | 6 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2013 | 223 | 0.030 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2014 | 231 | 0.030 |
Why?
|
| Rhabdomyosarcoma | 1 | 2016 | 342 | 0.030 |
Why?
|
| Cystoscopy | 1 | 1993 | 92 | 0.030 |
Why?
|
| Platelet Count | 1 | 2014 | 488 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 1420 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2014 | 329 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2014 | 6233 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2018 | 824 | 0.030 |
Why?
|
| Manometry | 1 | 2012 | 71 | 0.030 |
Why?
|
| Data Collection | 1 | 2015 | 602 | 0.030 |
Why?
|
| Platinum | 1 | 2013 | 142 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 2016 | 428 | 0.030 |
Why?
|
| Epidermis | 1 | 1993 | 197 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2011 | 7055 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2013 | 251 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 3190 | 0.030 |
Why?
|
| Gastroscopy | 1 | 2012 | 156 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2014 | 480 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 1993 | 186 | 0.020 |
Why?
|
| Medicaid | 1 | 2015 | 306 | 0.020 |
Why?
|
| Gastrointestinal Motility | 1 | 2012 | 87 | 0.020 |
Why?
|
| Genome, Human | 1 | 2020 | 1896 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 5759 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2014 | 501 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2016 | 675 | 0.020 |
Why?
|
| Pericardium | 1 | 2013 | 147 | 0.020 |
Why?
|
| Obesity | 2 | 2016 | 2895 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 322 | 0.020 |
Why?
|
| Health Status | 1 | 2015 | 626 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2015 | 1562 | 0.020 |
Why?
|
| Prevalence | 1 | 2019 | 3395 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1072 | 0.020 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 2011 | 15 | 0.020 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 1 | 2011 | 11 | 0.020 |
Why?
|
| Pulmonary Surfactant-Associated Protein B | 1 | 2011 | 14 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2006 | 4148 | 0.020 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2011 | 50 | 0.020 |
Why?
|
| Dumping Syndrome | 1 | 2010 | 7 | 0.020 |
Why?
|
| Elective Surgical Procedures | 1 | 2012 | 248 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2018 | 17072 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3929 | 0.020 |
Why?
|
| Biomarkers | 1 | 2022 | 5048 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2016 | 930 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2010 | 217 | 0.020 |
Why?
|
| Tertiary Care Centers | 1 | 2012 | 419 | 0.020 |
Why?
|
| Acute Disease | 2 | 2007 | 2492 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2013 | 483 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2396 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 5692 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 4494 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 1993 | 1030 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 2016 | 951 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2012 | 537 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2011 | 757 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 2009 | 111 | 0.020 |
Why?
|
| International Cooperation | 1 | 2010 | 326 | 0.020 |
Why?
|
| Quality of Life | 1 | 2023 | 4810 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 3345 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2013 | 1060 | 0.020 |
Why?
|
| Prostatectomy | 1 | 1993 | 1003 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 503 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 6193 | 0.020 |
Why?
|
| Thoracic Vertebrae | 1 | 2009 | 200 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 9048 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2009 | 352 | 0.020 |
Why?
|
| Prostate | 1 | 1993 | 1090 | 0.020 |
Why?
|
| Lip | 1 | 1987 | 35 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 694 | 0.020 |
Why?
|
| Vena Cava, Superior | 1 | 2007 | 77 | 0.020 |
Why?
|
| Surgical Stapling | 1 | 2007 | 35 | 0.020 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 368 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 3057 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2008 | 315 | 0.020 |
Why?
|
| Esophageal Stenosis | 1 | 2007 | 91 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 7052 | 0.020 |
Why?
|
| ras Proteins | 1 | 2011 | 804 | 0.020 |
Why?
|
| Paclitaxel | 2 | 2004 | 2114 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2006 | 251 | 0.020 |
Why?
|
| Drug Costs | 1 | 2007 | 140 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 3606 | 0.020 |
Why?
|
| Ketoconazole | 1 | 1985 | 36 | 0.020 |
Why?
|
| Blastomycosis | 1 | 1985 | 18 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2007 | 654 | 0.020 |
Why?
|
| Models, Educational | 1 | 2006 | 92 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 4644 | 0.020 |
Why?
|
| Hospitalization | 1 | 2015 | 2170 | 0.020 |
Why?
|
| Visual Perception | 1 | 2006 | 152 | 0.020 |
Why?
|
| Mitomycin | 1 | 2006 | 216 | 0.020 |
Why?
|
| Capecitabine | 1 | 2006 | 391 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 1986 | 277 | 0.020 |
Why?
|
| Suture Techniques | 1 | 2007 | 293 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 1344 | 0.020 |
Why?
|
| Life Tables | 1 | 2004 | 118 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4394 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2007 | 580 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2011 | 930 | 0.010 |
Why?
|
| Fetus | 1 | 1987 | 671 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 1986 | 291 | 0.010 |
Why?
|
| Abdomen | 1 | 2005 | 346 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 886 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 497 | 0.010 |
Why?
|
| Image Enhancement | 1 | 2007 | 553 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2004 | 334 | 0.010 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2005 | 277 | 0.010 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2008 | 449 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2008 | 837 | 0.010 |
Why?
|
| Deglutition Disorders | 1 | 2007 | 488 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 13994 | 0.010 |
Why?
|
| Heart Arrest, Induced | 1 | 2002 | 83 | 0.010 |
Why?
|
| Equipment Design | 1 | 2005 | 1207 | 0.010 |
Why?
|
| Oxygen | 1 | 1986 | 786 | 0.010 |
Why?
|
| Emergency Treatment | 1 | 2002 | 105 | 0.010 |
Why?
|
| Aortic Rupture | 1 | 2002 | 115 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2007 | 1323 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2006 | 1389 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2018 | 12042 | 0.010 |
Why?
|
| Apoptosis | 1 | 2014 | 7755 | 0.010 |
Why?
|
| Algorithms | 1 | 2009 | 3906 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2008 | 4104 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 5777 | 0.010 |
Why?
|
| Brachytherapy | 1 | 2003 | 1005 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1986 | 3841 | 0.010 |
Why?
|
| Melanoma, Experimental | 1 | 1997 | 381 | 0.010 |
Why?
|
| Random Allocation | 1 | 1993 | 727 | 0.010 |
Why?
|
| Reference Values | 1 | 1993 | 1127 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 1987 | 223 | 0.000 |
Why?
|
| Macaca mulatta | 1 | 1987 | 690 | 0.000 |
Why?
|
| Endocrine System Diseases | 1 | 1985 | 89 | 0.000 |
Why?
|
| Lung Diseases, Fungal | 1 | 1985 | 132 | 0.000 |
Why?
|
| Wound Healing | 1 | 1987 | 771 | 0.000 |
Why?
|
| Pregnancy | 1 | 1987 | 7916 | 0.000 |
Why?
|